Ozempic and longevity

GLP-1 agonists are lab-made copies of a fullness hormone. Most are a weekly injection. They help with weight loss, and in high-risk patients they also protect the heart and kidneys.

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after a meal. It tells your brain you're full, slows how fast your stomach empties, and helps control insulin.

GLP-1 agonists copy that signal but stay in the body much longer than the real thing. The main drugs:

• Semaglutide, sold as Ozempic (diabetes) or Wegovy (obesity). Weekly injection. Since 15 July 2026 the EU has also approved a once-daily Wegovy pill (oral semaglutide, up to 25 mg) and a single-dose 7.2 mg Wegovy pen ^[16]. The pill is prescription-only too.
• Tirzepatide, sold in the EU as Mounjaro for type 2 diabetes and obesity. In the US, the obesity brand is Zepbound (not marketed in the EU). It hits two hunger receptors instead of one (GLP-1 plus GIP).
• Liraglutide, the older version. Daily injection.

These drugs were built for type 2 diabetes. But the weight loss in trials was so large (10 to 22 percent of body weight in phase-3 studies) that regulators also cleared them for obesity.

The longevity question is a separate one. Do they help people live longer or healthier, beyond the weight loss itself?

This guide is not medical advice. GLP-1 agonists are prescription drugs with real risks. Talk to your doctor.

Short answer: no. Losing weight and living longer are related, but they are not the same thing.

Long-running observational studies show obesity (BMI over 30) is linked to several years of lost life expectancy. So reversing obesity should, in theory, win some of those years back. The reality is more complicated.

Here is what the data say:

• The method matters a lot. Bariatric surgery cut deaths from any cause by roughly 20 to 30 percent over 10-plus years (the SOS cohort, a controlled but not randomised study, NEJM 2007) ^[6]. Lifestyle-only weight loss did not reduce heart events in people with type 2 diabetes. That was the Look AHEAD trial, stopped early in 2012 because it could no longer show a benefit (futility) ^[7]. So the benefit seems to depend on how the weight comes off, not just on the weight loss itself.
• In people with a normal BMI, there is no evidence yet that GLP-1 extends life. Every trial has been run in people with obesity or diabetes.
• Weight loss costs you lean body mass, usually about 25 to 40 percent of the weight you drop (roughly 25 percent on tirzepatide, up to about 40 percent on semaglutide in STEP-1) ^{[18, 19]}. Lean body mass (what a DEXA scan reports) includes skeletal muscle plus water, glycogen, bone, and organ tissue, so the pure muscle share is smaller. But the skeletal-muscle loss on GLP-1s is real. Losing it risks worse mobility and metabolic health later, unless you add strength training and enough protein. We cover this in depth in our guide on keeping muscle on GLP-1.

So the real longevity question becomes: are there benefits beyond the weight loss itself? The human data are still too young to say. The first 2026 studies on aging itself are covered in the next section.

The big trials show real organ protection in high-risk groups. Semaglutide cut major heart events by 20 percent in people with obesity and heart disease (SELECT) ^[1]. It cut major kidney events by 24 percent in people with type 2 diabetes and kidney disease (FLOW) ^[3]. SELECT also saw a 19 percent drop in deaths from any cause, though that result is only nominal (not statistically confirmed). What the trials do not yet show is a direct lifespan benefit in humans, or any benefit at a healthy weight.

Three large randomised trials drive the current longevity debate.

SELECT (NEJM 2023) matters most ^[1]. It enrolled 17,604 people with overweight or obesity (BMI ≥27) and existing heart disease, but no diabetes. They took semaglutide 2.4 mg weekly for a mean of about 34 months, with mean follow-up of about 40 months.

• Heart events: 20 percent fewer heart attacks, strokes or cardiovascular deaths. This was the trial's main goal, called 3P-MACE (HR 0.80, 95 percent CI 0.72 to 0.90). HR is the hazard ratio: 0.80 means 20 percent lower risk. The CI is the range the true value most likely falls in.
• Deaths from any cause: 19 percent fewer (HR 0.81, 95 percent CI 0.71 to 0.93). But this number is only nominal. The trial tested its goals in a fixed order, and an earlier goal in that line missed its threshold. So the death result is a lead to follow up (hypothesis-generating), not a confirmed finding.

It's still the strongest evidence so far for a heart-protective, and possibly lifespan-related, effect.

STEP-HFpEF (2023) tested semaglutide in people with heart failure (the kind where the heart pumps but stays stiff) plus obesity ^[2]. Symptoms and exercise capacity improved.

FLOW (2024) tested semaglutide 1.0 mg in people with type 2 diabetes and chronic kidney disease ^[3]. The result: a 24 percent drop in major kidney disease events (a kidney-led composite that also counts cardiovascular death). Secondary results included an 18 percent drop in major heart-and-blood-vessel events (MACE) and a 20 percent drop in all-cause death.

Does semaglutide slow aging itself? Two 2026 studies made headlines. In Nature, UC Berkeley researchers gave semaglutide to 20-month-old female mice, which is old for a mouse, and kept treating them for life. Median lifespan rose from 742 to 834 days, about 12 percent ^[12]. The treated mice also did better than mice on a matched calorie cut on exploring, spatial memory and blood-sugar control. Mice are not people, and only females were tested. In humans, the evidence is an after-the-fact (post hoc) analysis of a 32-week placebo-controlled trial in 84 adults with HIV-related fat build-up. On semaglutide, their pace of aging on the DunedinPACE epigenetic clock ran 9 percent slower ^[13]. That clock is a blood test that reads chemical tags on your DNA. It was not a planned goal of the trial, and a slower clock is a biomarker, not a longer life.

Then there is the liver. MASH (metabolic dysfunction-associated steatohepatitis) is fatty liver that has turned into inflammation and scarring. F2-F3 fibrosis means moderate to advanced scarring, short of cirrhosis.

• US: on 15 August 2025, the FDA approved Wegovy (semaglutide 2.4 mg) for noncirrhotic MASH with F2-F3 fibrosis, based on ESSENCE Part 1 results ^[21].
• EU: the EMA's drug committee (CHMP) gave a positive opinion on 29 January 2026. The European Commission granted conditional marketing authorisation on 26 March 2026, under the brand name Kayshild, valid EU-wide ^[24]. Conditional means more proof is owed: the ongoing ESSENCE Part 2 trial, with a 240-week clinical-event read-out expected 2029.
• Tirzepatide has no MASH approval in the EU as of September 2026, despite social-media claims to the contrary. The published evidence so far is the Phase 2 SYNERGY-NASH trial (NEJM 2024) ^[11].

Next-generation candidates worth watching.

Orforglipron (Eli Lilly, US brand Foundayo) is the first oral non-peptide GLP-1 receptor agonist: a pill you can take any time of day, with no food or water rules. The FDA approved it on 1 April 2026 for adults with obesity, or overweight plus weight-related medical problems. It went through the FDA's CNPV pilot (Commissioner's National Priority Voucher; NDA 220934). At about 50 days from filing, it was the fastest approval of a brand-new drug substance (NME) since 2002. Phase 3 read-outs:

• ACHIEVE-1 (early type 2 diabetes): HbA1c, a 3-month blood-sugar average, fell about 1.2 to 1.5 percentage points across doses at 40 weeks (NEJM 2025) ^[23].
• ATTAIN-1 (obesity): 11.2 percent mean weight loss at 72 weeks on the highest 36 mg dose, versus 2.1 percent on placebo (NEJM 2025) ^[22].
• ATTAIN-2 (obesity plus type 2 diabetes).

In Europe, the UK regulator MHRA authorised Foundayo on 10 August 2026 for weight management and type 2 diabetes, the first European approval. As of September 2026 it is not authorised in the EU, so you cannot get it on prescription in Germany or Austria.

Retatrutide, also from Eli Lilly, hits three receptors at once (GLP-1, GIP and glucagon). Its first positive Phase 3 result came in December 2025, from TRIUMPH-4 in people with obesity plus knee osteoarthritis. Mean weight loss reached up to 28.7% at the highest dose, with significant pain reduction. The main obesity trial TRIUMPH-1 (2,339 adults) followed with positive topline results on 21 May 2026: people with severe obesity on the highest dose lost up to about 30 percent of their body weight over two years. Both are Eli Lilly press releases, not peer-reviewed papers. Retatrutide is not FDA- or EMA-approved as of September 2026, and approval is not expected before 2027. On 26 August 2025, Swissmedic (the Swiss drug regulator) warned about falsified "retatrutide injection kits" sold on social media. Outside trials, the substance stays research-only.

What we still don't know:

• Direct human lifespan data over 10-plus years
• The effect in people without risk factors (healthy-weight BMI)
• Long-term safety across multiple decades
• Whether the benefits stick around after you stop (early hint: most of the weight comes back within 1 to 2 years) ^{[5, 17]}
• The brain: in the phase 3 evoke and evoke+ trials, oral semaglutide did not slow early Alzheimer's disease ^[15]

SELECT-LIFE, a survey-based observational follow-up of about 3,400 SELECT participants after they stopped the study drug, finished data collection in August 2025 (ClinicalTrials.gov NCT04972721). It was not randomised, so hard lifespan answers will still need a dedicated trial.

GLP-1 agonists are prescription drugs with real side effects, not harmless supplements. The most common is nausea, hitting up to about 45 percent of users early on (44 percent on Wegovy 2.4 mg in the STEP trials, per the EU label ^[16]), alongside diarrhoea, constipation, and vomiting. Rare but serious risks include pancreatitis, gallstones, gastroparesis, and a very rare signal for sudden vision loss (NAION). The risks come in two tiers.

Common (roughly 1 in 4 to 1 in 2 users at obesity doses):

• Nausea, especially in the first weeks
• Diarrhoea or constipation
• Vomiting
• Loss of appetite (that's the point, but it can tip into eating too little)

Less common but serious:

• Pancreatitis (inflamed pancreas). Get medical help right away.
• Gallbladder problems, including a higher risk of gallstones and cholecystitis.
• Gastroparesis (the stomach empties too slowly). If you have surgery or deep sedation coming up, tell your anaesthetist you take a GLP-1. Food left in the stomach can get into the lungs under anaesthesia (pulmonary aspiration), and cases have been reported. The pause advice has changed. The ASA (American Society of Anesthesiologists) 2023 consensus suggested pausing weekly GLP-1 agonists for one week, and daily ones on the day of the procedure. The October 2024 update from five societies (ASA, AGA, ASMBS, ISPCOP, SAGES) softened that universal rule ^[20]. It now weighs each person's risk and decides with them (for example gastric ultrasound or diet changes beforehand), instead of stopping the drug automatically. Discuss any pre-op pause with your prescriber.
• Acute kidney injury from dehydration, if nausea or vomiting stops you drinking enough fluid.
• Medullary thyroid carcinoma (MTC) and MEN-2 (Multiple Endocrine Neoplasia type 2, an inherited tumour syndrome): the US label has a boxed warning and does not allow use if you or a close relative has had MTC or MEN-2. The EU label has no such warning. It mentions thyroid C-cell tumours only in rodent studies (SmPC section 5.3) and rates the human relevance as low ^[16]. Many doctors still avoid these drugs if you have that history.
• NAION (non-arteritic anterior ischaemic optic neuropathy): sudden vision loss when blood flow to the optic nerve drops. It is very rare. The first signal came from a single-centre cohort on semaglutide (JAMA Ophthalmology 2024): hazard ratio 4.28 (95 percent CI 1.62 to 11.29) ^[4]. A much larger OHDSI analysis across 14 databases and 37.1M adults with type 2 diabetes (JAMA Ophthalmology, April 2025) found a smaller rise: rate ratio (IRR) about 1.32 (95% CI 1.14 to 1.54) ^[9]. Its authors called it "a modest increase in the risk of NAION... smaller than that previously reported." A Danish-Norwegian cohort (Diabetes, Obesity and Metabolism 2025) reported a pooled HR of 2.81 (95% CI 1.67 to 4.75) ^[10]. After the EMA safety committee (PRAC) concluded its review in June 2025, semaglutide product information was updated through autumn 2025 ^[25]. It now lists NAION as a very rare side effect (under 1 in 10,000). If you notice sudden, painless vision loss, see an eye doctor urgently.
• Diabetic retinopathy worsening in patients who already have retinopathy (the SUSTAIN-6 signal).
• Muscle and bone loss if you don't plan around it.

Mental health: Reports of mood changes and, in a few cases, suicidal thoughts are still being reviewed by regulators. The EMA PRAC concluded in April 2024 that no cause-and-effect link was proven, but monitoring continues.

Cost and supply (Germany):

• Obesity: always self-pay. Statutory health insurance (GKV) excludes Wegovy and Mounjaro for obesity as lifestyle drugs (§34 Abs. 1 Satz 7 and 8 SGB V; AM-RL Anlage II) ^[8]. Expect roughly €170 to 500 per month depending on drug and dose (Mounjaro about €206 to 482). Current prices per dose are in our cost comparison.
• Type 2 diabetes: reimbursed. Ozempic (semaglutide, up to 2 mg) and Mounjaro are covered on the approved indication, via your diabetologist or internist.
• Off-label Ozempic for obesity without diabetes breaks GKV rules. The KBV (the national body of statutory-insurance doctors) has repeatedly written about it.
• Fakes: BfArM (Germany's drug regulator) warned in 2023 to 2024 about counterfeit Ozempic from grey-market imports during the shortage. Only fill prescriptions at licensed pharmacies.

It depends on where you start. If you have obesity or type 2 diabetes, GLP-1 agonists are among the most effective tools available, with proven heart and kidney benefits. Discuss them with a doctor. At a normal weight, taking them purely for longevity is speculation: no supporting evidence in humans, same real risks. Either way, strength training and protein are non-negotiable.

If you have obesity or type 2 diabetes: the data now back this ^{[1, 3]}. Make the decision with a doctor, ideally one with endocrinology or cardiology expertise.

At a normal weight, optimising for longevity: this is speculation, not science. Off-label low-dose use gets talked about in longevity circles (especially in the US), but the evidence is basically not there. The known risks (muscle loss, gut side effects, rare serious problems) don't disappear just because the proven benefit isn't there yet.

Non-negotiable companions to any GLP-1 use:

• Strength training (2 to 3 times a week) to keep muscle
• Higher protein intake (1.6 to 2.0 g per kg body weight)
• Regular DEXA or InBody scans to track body composition
• Heart checkups and blood work per your doctor's plan

Who qualifies in Germany (Austria and Switzerland have different insurance rules):

• BMI ≥30 on its own (obesity), or BMI 27 to under 30 plus at least one weight-related condition: Wegovy is indicated per the EMA product information (SmPC) ^[16]. Qualifying conditions: blood-sugar problems (dysglycaemia, prediabetes or type 2 diabetes), high blood pressure, abnormal blood fats (dyslipidaemia), obstructive sleep apnoea, or cardiovascular disease. BMI ≥30 does not require any of these. Statutory insurance (GKV) will not pay for obesity (the AM-RL Anlage II lifestyle-drug exclusion) ^[8]. A private prescription (Privatrezept) from your GP (Hausarzt) or a specialist obesity practice (Adipositas-Schwerpunktpraxis) is legal and standard. Self-pay runs roughly €170 to 500 per month depending on drug and dose.
• Type 2 diabetes (any BMI) means Ozempic or Mounjaro are reimbursed by GKV on indication, via your diabetologist or internist.
• Normal BMI, seeking "longevity" means no clinical indication. Off-label prescribing for this purpose is very rare in Germany and not supported by existing trials.

Monitoring checklist:

• Baseline (before first injection): HbA1c, TSH, fasting glucose, lipid panel, lipase, eGFR, liver enzymes. Pregnancy test where relevant. Document starting weight and body composition (DEXA or InBody) if possible.
• Weeks 0 to 16 (titration): nausea is normal early. Slow the dose escalation if vomiting persists for ≥1 week. Track weight weekly.
• Quarterly ongoing: HbA1c, lipid panel, lipase, renal function. DEXA or InBody every 6 months to catch lean-mass loss.
• Reasons to contact your prescriber promptly: persistent vomiting or dehydration, lipase rising above 3× the upper limit of normal, gallbladder pain, unexplained neck swelling, pregnancy.

Muscle-protection protocol: These are points to raise with the prescribing physician, not a self-managed protocol. Minimum while on GLP-1: 3 full-body strength sessions per week at RPE 7 to 8, 2 to 3 reps in reserve. Protein 1.6 to 2.0 g per kg body weight. DEXA at baseline and 6 months. If lean-mass loss exceeds 10% over 6 months, your prescriber may consider slowing or pausing the dose.

Women's-health note: Tirzepatide (Mounjaro) briefly lowers blood levels of the pill. The US label advises switching to a non-oral method or adding a condom for 4 weeks after starting and 4 weeks after each dose increase. The EU label calls the drop not clinically relevant. Semaglutide does not weaken the pill. Severe vomiting or diarrhoea can weaken any pill, so ask your gynaecologist. Neither drug is for use in pregnancy, and human data are limited. EU labels say to stop semaglutide at least 2 months, and tirzepatide at least 1 month, before a planned pregnancy.

What the research actually says: a healthy body is the means, not the goal. Any tool that reverses obesity has plausible longevity potential. But thinness at any cost is not a health goal. GLP-1 with training is not the same outcome as GLP-1 without training.